Physician profile
Jack K Gray
NPI 1295708519
$8,507.86
in general payments reported to CMS, 2019-2025
27 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $1,088 · 2021: $1,188 · 2022: $1,252 · 2023: $1,667 · 2024: $1,757 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,425.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,495.18 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $934.79 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $873.79 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $801.13 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $680.48 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $488.39 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $448.56 | 2020-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $443.35 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $350.63 | 2024-2025 | Cobenfy |
| Corium, LLC | $330.15 | 2021-2023 | Azstarys |
| Alkermes, INC. | $244.21 | 2021-2025 | Lybalvi, Aristada |
| Allergan, INC. | $200.09 | 2019-2020 | |
| Lundbeck LLC | $198.53 | 2019-2023 | Rexulti |
| Axsome Therapeutics, INC. | $186.65 | 2023-2025 | Auvelity |
| Tris Pharma INC | $185.08 | 2020-2025 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $173.14 | 2019-2024 | Fanapt |
| Neurocrine Biosciences, INC. | $107.16 | 2022-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $103.07 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $59.56 | 2020-2021 | |
| Noven Therapeutics, LLC | $53.71 | 2024-2025 | Xelstrym, Secuado |
| Almatica Pharma LLC | $46.36 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Neos Therapeutics, Lp | $44.52 | 2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $14.98 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.82 | 2020 | |
| Rhodes Pharmaceuticals L.P. | $13.28 | 2019 | |
| Shire North American Group INC | $12.34 | 2019 | |
| Sumitomo Pharma America, INC. | $4.91 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.